CN1626242A - Combined vaccine composed of viral of Japanese b encephalitis and vaccine of brain fever cocci - Google Patents
Combined vaccine composed of viral of Japanese b encephalitis and vaccine of brain fever cocci Download PDFInfo
- Publication number
- CN1626242A CN1626242A CN 200310119414 CN200310119414A CN1626242A CN 1626242 A CN1626242 A CN 1626242A CN 200310119414 CN200310119414 CN 200310119414 CN 200310119414 A CN200310119414 A CN 200310119414A CN 1626242 A CN1626242 A CN 1626242A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- encephalitis
- combined vaccine
- virus
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 172
- 210000004556 brain Anatomy 0.000 title description 8
- 230000003612 virological effect Effects 0.000 title description 8
- 206010014596 Encephalitis Japanese B Diseases 0.000 title 1
- 201000005807 Japanese encephalitis Diseases 0.000 title 1
- 206010037660 Pyrexia Diseases 0.000 title 1
- 206010014599 encephalitis Diseases 0.000 claims abstract description 98
- 201000009906 Meningitis Diseases 0.000 claims abstract description 94
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 241000700605 Viruses Species 0.000 claims description 78
- 150000004676 glycans Chemical class 0.000 claims description 60
- 229920001282 polysaccharide Polymers 0.000 claims description 60
- 239000005017 polysaccharide Substances 0.000 claims description 60
- 101710116435 Outer membrane protein Proteins 0.000 claims description 26
- 230000009849 deactivation Effects 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 17
- 210000003501 vero cell Anatomy 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 11
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 241000699800 Cricetinae Species 0.000 claims description 6
- 210000003292 kidney cell Anatomy 0.000 claims description 6
- 210000002845 virion Anatomy 0.000 claims description 6
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 239000004411 aluminium Substances 0.000 claims description 4
- 238000005336 cracking Methods 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 3
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 2
- 230000000680 avirulence Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 2
- 210000001840 diploid cell Anatomy 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 239000007788 liquid Substances 0.000 abstract description 16
- 238000012412 chemical coupling Methods 0.000 abstract description 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 abstract description 2
- 238000012258 culturing Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 42
- 102000036639 antigens Human genes 0.000 description 42
- 108091007433 antigens Proteins 0.000 description 42
- 238000002360 preparation method Methods 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 21
- 239000011550 stock solution Substances 0.000 description 19
- 230000008878 coupling Effects 0.000 description 16
- 238000010168 coupling process Methods 0.000 description 16
- 238000005859 coupling reaction Methods 0.000 description 16
- 230000005847 immunogenicity Effects 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 241000588650 Neisseria meningitidis Species 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 229940031551 inactivated vaccine Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000011218 seed culture Methods 0.000 description 6
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 5
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 4
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000013223 septicemia Diseases 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 241001478240 Coccus Species 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000037941 meningococcal disease Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229940031937 polysaccharide vaccine Drugs 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000009781 safety test method Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001536481 Banzi virus Species 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- -1 adipoyl hydrazine Chemical compound 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 229940052778 neisseria meningitidis Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A combined vaccine for preventing encephalitis B, meningitis and septemia is prepared through culturing the encephalitis B virus, deactivating, ultrafiltering for concentrating, purifying to obtain the raw liquid of encephalitis B, chemical coupling of the outer membrain protein of meningococcus B with the polyoses of meningococcus A and C to obtain another raw liquid, and mixing it with said raw liquid of encephalitis B.
Description
Technical field
The present invention relates to a kind of combined vaccine of forming by encephalitis b virus vaccine and meningococcus combined vaccine.Particularly, the present invention relates to a kind of encephalitis b virus purification stock solution and A, C group meningitis cocci polysaccharide antigen and a protein carrier coupling stock solution and be mixed with a kind of novel combined vaccine jointly.More specifically, the encephalitis b virus stock solution that the present invention relates to is the encephalitis b virus stock solution that encephalitis b virus obtains through Vero cell culture, results, deactivation, ultrafiltration and concentration, purification.The meningococcal polysacharide protein binding stock solution that the present invention relates to is that the A group meningitis cocci polysaccharide of purification and C group meningitis cocci polysaccharide carry out chemical coupling with B group meningitis cocci outer membrane protein respectively and the conjugate stock solution that forms.Two kinds of stock solutions are mixed with prevention encephalitis B and meningitic combined vaccine through adding certain density suitable protective agent and/or adjuvant.The invention still further relates to the preparation method of this combined vaccine.
Background technology
Encephalitis B disease and pathogen thereof:
Encephalitis B is the disease of central nervous system's acute viral infection, and up to 10～1,00/,100,000, nearly 3,000,000,000 populations are lived in the popular district of encephalitis B at popular regional annual morbidity, and the annual neonate in this area just surpasses 7,000 ten thousand.In the viral encephalitis in Asia, encephalitis B is the most serious disease.At least cause that 50,000 clinical cases and 10,000 examples die of illness every year, the overwhelming majority betides among the child.In decades recently, several outbreak of epidemic of encephalitis B are the popular area of the right and wrong of betiding over all, follow very high case fatality rate and serious persistency nervous system sequela simultaneously, thus in the Asia a lot of countries and regions, encephalitis B becomes serious public health problem.
Epidemic encephalitis B virus (Japanese Encephalitis Virus) is called for short encephalitis b virus, and virion is the icosahedron symmetrical structure, and diameter 45-50nm has peplos.Belong to a kind of of banzi virus, gene is the normal chain single-stranded RNA, and the RNA bag is formed the core of virion by in the capsid C of sub-thread polypeptide, and glycosylated protein E and non-glycosylated protein M are arranged in its peplos.
Mosquito is the main communication media of encephalitis b virus in the encephalitis B route of infection, and pig is main intermediate host.The people is because of being infected by viruliferous mosquito bite.
Also do not treat at present the medicine of encephalitis B disease, do not control the effective ways of its propagation yet from the environment aspect.The immunity inoculation of Vaccinum Encephalitis B is the of paramount importance measure of control encephalitis B disease.
Epidemic cerebrospinal meningitis disease and pathogen:
The Neisseria meningitidis associated diseases is a key factor that causes serious disease and high mortality in the world wide.Before sulfanilamide and antibiotics invention, the meningococcal disease case fatality rate is about 70%.Today, although the good curing measure is arranged, even case fatality rate that should disease in developed country still can be up to 10%, and the septicemia case fatality rate of its initiation more can surpass 50%.The scorching coccus of neisseria meningitis has caused that 500,000 cases and 50,000 examples are dead every year in the whole world.
The Neisseria meningitidis popular name is a meningococcus, and formal name used at school is Neisseriameningitidis, is also referred to as the scorching coccus of neisseria meningitis sometimes.Neisseria meningitidis is aerobe, and Gram-negative has the double row of the normal one-tenth of pod membrane, so be called diplococcus again.Because no pod membrane bacterial strain causes clinical disease hardly, so pod membrane has been played the part of important function aspect bacterial virulence.Difference according to the capsular polysaccharide characteristic can be divided into 13 sero-group: A, B, C, D, E29, H, I, K, L, W135, X, Y, Z at least.But only belong to A, B, C, the arbitrary group among these 5 groups of Y and W135 just can be caused a disease, and 90% meningococcal disease is caused by A, B, three crowds of C.
Neisseria meningitidis is a pathogen main in the whole world bacterial meningitis.The world is unique to cause the popular antibacterial of meningitis large-scale outbreak.Even good medical condition is arranged, the acute cerebral meningitis coccus often can produce dead in one or two days in the morbidity back or stay serious sequela.Chemical drugs almost is not worth for the control disease eruption and prevalence.What is more important is used and/or abuse along with antibiotics is a large amount of, and many places comprise that Chinese meningococcus rolls up the drug resistance of antibiotics in the world, just make and prevent and control this disease to become urgent task by the immunity inoculation vaccine.
Existing Vaccinum Encephalitis B situation:
Vaccinum Encephalitis B has 3 classes in large-scale application, inactivated vaccine of cultivating through the inactivated vaccine of murine brain propagative viruses and purification preparation, through cell (Ren Mus primary cell or Vero passage cell) and the attenuated live vaccine of cultivating through cell (Ren Mus primary cell).Through the inactivated vaccine of murine brain propagative viruses and purification, though through purification process, but still the residual murine brain composition that denier is arranged is that one of anaphylactoid principal element takes place.With the inactivated vaccine and the attenuated live vaccine of hamster kidney cell preparation, because used suslik is not SPF (no-special pathogen) level, this is difficult to be avoided exogenous factor to pollute, and this possible pollution is again to be difficult to detect with existing biological method.Therefore, can not make vertification regulation by World Health Organization's vaccine and be admitted (the Ze literary composition is far away, planned immunization, Shanghai scientific and technical literature publishing house, calendar year 2001,476～495 pages).And through the deactivation purified vaccine of Vero cell culture preparation even more ideal aspect safety and the effectiveness than other vaccine.At first, vaccine virus kind seed bank is through the preparation of Vero passage, has avoided other vaccine because of the preparation seed that goes down to posterity with murine brain fully, the murine brain composition of residual minim.Secondly, viral seed prepares vaccine through the Vero cell proliferation, and the exogenous factor of having avoided causing with murine brain or hamster kidney cell propagative viruses pollutes.
Existing meningococcus vaccine situation:
Meningococcus vaccine has two big classes, and a class is unit price, bivalence and the tetravalence polysaccharide antigen with meningococcus capsular polysaccharide antigen preparation, and another kind of is with meningococcus folder film polysaccharide antigen and the protein carrier combined vaccine of coupling preparation mutually.Because polysaccharide antigen is a T cell dependent/non-dependent antigen, so polysaccharide vaccine unprotect effect in child below two years old.Combined vaccine is then changed into T cell dependence antigen with polysaccharide antigen from T cell dependent/non-dependent antigen, makes combined vaccine can produce good immunological memory reaction and protective effect in child below two years old.What we researched and developed has good immunogenicity and immune anamnesis reaction with A, C group meningitis cocci polysaccharide and the link coupled combined vaccine of B group's outer membrane protein through the animal experiment proof.
Theoretical basis of the present invention:
Combined vaccine is the developing goal that WHO encourages always, and Shang Shi hepatitis A hepatitis B combined vaccine, measles, parotitis and rubella combined vaccine, whooping cough hepatitis B Hib combined vaccine etc. have shown that all combined vaccine is the important trend of vaccine development in recent years.The advantage of combined vaccine is to have reduced object of inoculation by frequency injection, has reduced rate of side effects, improves the vaccination rate, has saved social resources.And the research and development combined vaccine must be followed following principle; Associating back side reaction must not increase, and between the synantigen interference must not arranged, and immunogenicity is lowered with protecting render a service, and stability must not weaken, and to other vaccine that enters immune programme for children interference effect must not be arranged.Encephalitis of the present invention and meningitis combined vaccine have been inherited the advantage of above-mentioned combined vaccine just and have been followed the principle of above-mentioned combined vaccine.
About encephalitis and meningitis combined vaccine, those skilled in the art think that existing Inactivated Japanese Encephalitis Vaccine and meningococcus combined vaccine are to make combined vaccine.Its reason is: the immune programme for children difference of the first, two kind of vaccine.The immune programme for children of Inactivated Japanese Encephalitis Vaccine is two doses of inoculations in 0,7 day, 1 year reinforcement potion.The immune programme for children of meningococcus combined vaccine is 0,1, inoculate three doses February.The second, the extensive now Vaccinum Encephalitis B that uses is the inactivated vaccine of murine brain inactivated vaccine, hamster kidney cell cultivation and the attenuated live vaccine that hamster kidney cell is cultivated, and the safety of these vaccines self is all in urgent need to be improved.The 3rd, existing meningococcal polysaccharide vaccine is to the effect of the unprotect of child below two years old.
The present invention thinks that then Inactivated Japanese Encephalitis Vaccine and meningococcus combined vaccine are to make combined vaccine.Its reason is: the first, existing Inactivated Japanese Encephalitis Vaccine is because the side reaction cause, every dose of antigenic content is lower, so the fundamental immunity interval weak point be 7 days.The used Inactivated Japanese Encephalitis Vaccine of the present invention is that virus is made through Vero cell culture, deactivation, ultrafiltration and concentration, purification, has strengthened every dose of virus antigen content, improves vaccine immunogenicity and does not increase side reaction, makes fundamental immunity can extend to one month at interval.The immune programme for children of comprehensive again meningococcus combined vaccine, the immune programme for children of combined vaccine are 0,1,6～December.The second, do the A of carrier, immune efficacy and the safety that C group meningitis cocci combined vaccine has all solved self through the encephalitis B deactivation purified vaccine of Vero cell preparation with B group meningitis cocci outer membrane protein, make the preparation combined vaccine become possibility.The 3rd, combined vaccine is noiseless phenomenon between the synantigen not, and different immunogenicity of antigens and protection are renderd a service and not only be not lowered, and have occurred strengthening the effect of immune efficacy each other on the contrary.
In view of the foregoing, to be mixed with combined vaccine through the encephalitis B deactivation purified vaccine of Vero cell preparation with A, C group meningitis cocci combined vaccine that B group meningitis cocci outer membrane protein is made carrier, infect encephalitis and meningitis and the septicemia disease that causes because of encephalitis b virus and A, B, C group meningitis cocci in order to prevention infant, child, teenager and adult.
Therefore, the object of the present invention is to provide a kind of combined vaccine by the preparation of encephalitis b virus vaccine and meningococcus combined vaccine and preparation method thereof.
Summary of the invention
In order to finish purpose of the present invention, the invention provides a kind of combined vaccine, it is characterized in that comprising encephalitis b virus vaccine and meningococcus combined vaccine.
Among the present invention, described encephalitis b virus vaccine is the vaccine that a kind of complete virion that is obtained through cell culture, results, deactivation, ultrafiltration and concentration, purification by encephalitis b virus prepares.
For further eliminating the endogenous cytotoxic composition in the whole virus particles, described encephalitis b virus vaccine can also be that complete virion is again through chemical cracking agent cracking, extraction comprises the fragment of outer virionic membrane and furcella, the encephalitis b virus split vaccine of making.
Described encephalitis b virus vaccine is by SA
14Strain, SA
14-14-2Strain, P
3Arbitrary Strain prepares in strain or the Nakayama strain.
Among the present invention, described meningococcus combined vaccine be a kind of by A group meningitis cocci capsular polysaccharide and C group meningitis cocci capsular polysaccharide respectively with the link coupled combined vaccine of protein carrier.Described A group meningitis cocci polysaccharide is from bacterial strain CMCC (B) 29201, described C group meningitis cocci polysaccharide is from bacterial strain CMCC (B) 29205, and described B group meningitis cocci outer membrane protein is from bacterial strain CMCC (B) 29356 and/or CMCC (B) 29361.
Described meningococcus combined vaccine also a kind of by A group, C group, W135 group and Y group meningitis cocci capsular polysaccharide respectively with the mutually link coupled combined vaccine of B group meningitis cocci outer membrane protein.
Described protein carrier is selected from B group meningitis cocci outer membrane protein, tetanus toxoid, diphtheria toxoid, avirulence diphtheria variant (CRM197) toxin.
In addition, combined vaccine of the present invention contains aluminium adjuvants such as aluminium hydroxide and/or aluminum phosphate or other well known to a person skilled in the art adjuvant.
In the combined vaccine of encephalitis b virus vaccine of the present invention and the preparation of meningococcus combined vaccine, every dose of human combined vaccine contains encephalitis b virus albumen 5～50 μ g, A group meningitis cocci polysaccharide 5～50 μ g, C group meningitis cocci polysaccharide 5～50 μ g, B group meningitis cocci outer membrane protein 30～300 μ g.In other words, the invention provides a kind of deactivation purified encephalitis B viral vaccine of cultivating preparation through the Vero passage cell, be that two valency combined vaccines carrier and that form covalent coupling with A, C group meningitis cocci capsular polysaccharide respectively are mixed with a kind of new combined vaccine with this viral vaccine with B group meningitis cocci outer membrane protein again, the encephalitis and meningitis and the septicemia disease that cause because of encephalitis b virus and A, B, the infection of C group meningitis cocci in order to prevention infant, child, teenager and adult.The present invention also provides the encephalitis b virus stock solution that obtains through Vero cell culture, results, deactivation, ultrafiltration and concentration, purification with encephalitis b virus, again with A, carry out the two valency conjugate stock solutions that the chemical coupling remix becomes with the B group meningitis cocci outer membrane protein of making carrier respectively behind the C group meningitis cocci polysaccharide purification, through being mixed with a kind of method of new combined vaccine.
Emphasis is introduced among the present invention notion and method are, to through the encephalitis b virus deactivation purified vaccine of Vero cell culture preparation and the combined vaccine that forms with A, C group meningitis cocci polysaccharide and the coupling of B group meningitis cocci outer membrane protein, become a kind of new combined vaccine through preparation again.
Distinguishing feature of the present invention is the immune-enhancing effect of combined vaccine.Encephalitis B and meningitis combined vaccine are not that two kinds of vaccines are simply mixed.Combined vaccine side reaction after preparation does not increase, and various antigens do not disturb each other, but show antigen synergy each other.Different antigenic antigenicities and immunogenicity not only are not lowered, and occur immune-enhancing effect on the contrary.(1.618) are renderd a service in NAT (1: 20) and protection that associating back encephalitis b virus antigen NAT (1: 40) and protection effectiveness (1.827) are significantly higher than before the associating; associating back A group meningitis cocci immunogenicity of antigens (GMT 8792) is significantly higher than the immunogenicity (GMT 5861) before the associating, and associating back C group meningitis cocci immunogenicity of antigens (GMT7952) is significantly higher than the immunogenicity (GMT 5353) before the associating.
The used encephalitis b virus of the present invention (Japanese Encephalitis Virus) seed culture of viruses is bought in Nat'l Pharmaceutical ﹠ Biological Products Control Institute.The seed culture of viruses name is called: SA
14, SA
14-14-2, P
3, the Nakayama strain.
Nat'l Pharmaceutical ﹠ Biological Products Control Institute is responsible for preparation and provides above-mentioned viral seed culture of viruses, and the public can buy.
In one embodiment of the invention, encephalitis b virus is cultivated and can be adopted above-mentioned seed culture of viruses SA
14, SA
14-14-2, P
3, any strain in the Nakayama strain.If satisfy the demand, also can adopt other suitable seed culture of viruses, the seed culture of viruses that herein provides only is for illustrative the present invention.
The used Neisseria meningitidis of the present invention (Neisseria meningitidis) bacterial strain is bought in Chinese medicine antibacterial preservation center (CMCC), and its bacterial strain number is; CMCC (B) 29201 A4 strains, CMCC (B) 29205 C11 strains, CMCC (B) 29356 B4 strains, CMCC (B) 29361B15 strain.
The full name at Chinese medicine antibacterial preservation center is a medical microbial culture presevation administrative center, and above-mentioned bacterial strains is deposited in this center affiliated unit: Nat'l Pharmaceutical ﹠ Biological Products Control Institute, Beijing (NICPBP).This mechanism produces and sells these bacterial strains, and the public can buy.
In one embodiment of the invention, adoptable bacterial strain was CMCC (B) 29201 when A group meningitis cocci polysaccharide prepared, adoptable bacterial strain was CMCC (B) 29205 when C group meningitis cocci polysaccharide prepared, and B group meningitis cocci outer membrane protein when preparing adoptable bacterial strain be CMCC (B) 29356 and/or CMCC (B) 29361.If satisfy the demand, also can adopt other suitable bacterial strain, bacterial strain given here only is for illustrative the present invention.
Encephalitis b virus cultivating system of the present invention is the Vero cell, also human diploid cell, chick-embryo cell, hamster kidney cell.If satisfy the demand, also can adopt other suitable cell, the cell that herein provides only is for illustrative the present invention.
In the combined vaccine of the present invention, every dose of human immunizing dose of encephalitis b virus antigen is for containing virus protein 5～50 μ g, and A and C group meningitis cocci capsular polysaccharide have 5～50 μ g in every dose of human immunizing dose of described combined vaccine.As for the upper limit of consumption, those skilled in the art can finally determine according to combined vaccine human clinical trial data.
Can further add adjuvant, for example aluminium adjuvant such as aluminium hydroxide and/or aluminum phosphate in the combined vaccine of the present invention.During use, can dilute combined vaccine of the present invention, the example that does not limit of suitable diluent has the phosphate buffer diluent.
The immune programme for children of combined vaccine of the present invention is different from the immune programme for children of existing Vaccinum Encephalitis B and/or meningococcus vaccine, and the immune programme for children of combined vaccine is 0,1,6～December is inoculated 3 pins, and first pin is inoculated during 3～6 monthly ages the child.
In a word, also do not have at present a kind ofly new will be mixed with combined vaccine through the encephalitis B deactivation purified vaccine of Vero cell preparation with A, C group meningitis cocci combined vaccine that B group meningitis cocci outer membrane protein is made carrier.This combined vaccine infects encephalitis and meningitis and the septicemia disease that causes in order to prevention infant, child, teenager and adult because of encephalitis b virus and A, B, C group meningitis cocci.
The specific embodiment
Below in conjunction with embodiment the present invention is described;
Embodiment 1
The preparation of encephalitis b virus vaccinogen liquid and meningococcal polysacharide and protein binding vaccinogen liquid and the preparation of combined vaccine.
The preparation of encephalitis b virus vaccinogen liquid: the Vero cell is through passing 4 generations, 37 ℃ of cultivations continuously.The 4th generation cell culture after 72 hours, use phosphate buffer drip washing, the virus inoculation titre is the encephalitis b virus SA of 7.96PFU/ml
14Strain virus, and add cell maintenance medium in 35 ℃, cultivated 24 hours.Change to fresh cell maintenance medium, continue to cultivate cytopathy (CPE) 72 hours by above-mentioned condition ++～+++, gather in the crops, merge viral liquid.After keeping sample, add 20% formaldehyde, making its final concentration is 0.05%, puts 22 ℃, 8 days inactivation of viruses.After the inactivation test checking is qualified, with 300KD filter membrane ultrafiltration and concentration.Add the protamine sulfate of 10mg/ml in the viral liquid after concentrating, making its final concentration is 0.1mg/ml, 8, and after 000rpm is centrifugal, aseptic filtration.Through Sepharose 4FF gel filtration chromatography, collect viral peak liquid again, add an amount of human albumin, be stored in 2～8 ℃ as protective agent.After projects such as sterility test, remaining Ox blood serum mensuration, potency test mensuration is qualified, be the encephalitis b virus vaccinogen liquid.
The preparation of meningococcal polysacharide and protein binding vaccinogen liquid: the preparation of (1) B group meningitis cocci outer membrane protein: breakdown B group meningitis cocci inoculation is closed the inclined-plane in doup, expand bacterium and reach the liquid tank cultivation of the 5th generation, continuous centrifugal is collected thalline, with 0.3～0.6M LiCl and 0.2～0.5M CH
3The COONa mixture extracts outer membrane protein.35～45 ℃ vibrated 1～3 hour.Centrifugal 4000～8000 rev/mins * 1 hour, collect supernatant, add concentration of alcohol to 60～80% precipitation outer membrane protein then.After the injection solution redissolution, collect the 400KD filtrate by ultrafiltration, concentrate through the 30KD ultrafilter membrane again.Detect required 1,2 classes or 1,3 class 1 outer-membrane protein content with SDS-PAGE.Sephacryl S 200-400 chromatography is collected required 1,2 classes or 1,3 class 1 outer-membrane proteins.The purity (SDS-PAGE method) of detection protein content (Lowry method), Main Ingredients and Appearance and 1,2 classes or 1,3 class 1 outer-membrane proteins and endotoxin content (limulus reagent test), sterility test.(2) A group meningitis cocci capsular polysaccharide coupling stock solution: the details of the preparation method of A group meningitis cocci polysaccharide, referring to " Chinese biological goods rules " (Chemical Industry Press,, 80～85 pages in 2000).A group meningitis cocci capsular polysaccharide is diluted to 4mg/ml and adds the cyanogen bromide-activated polysaccharide, 23 ± 3 ℃ act on 1～1.5 hour down, transfer pH and keep pH9～11, continue after add adipoyl hydrazine 2.5～5mg/mgps, keep pH8～10 and act on 10～30 minutes, stirred 10～20 hours at 2～8 ℃, small-molecule substance is removed in dialysis, Bromine cyanide. residual volume, adipic dihydrazide derivation rate are surveyed in sampling.Add equivalent B group meningitis cocci outer membrane protein and mix with polysaccharide, add carbodiimide 15～25mg/ml mixture, 5～15 ℃ act on 1～1.5 hour, adjust PH5～7.Small-molecule substance is removed in the dialysis of coupling stock solution.300KD film bag ultrafiltration and concentration, through Sepharose CL-4B column chromatography, collect high-molecular weight coupling compound, aseptic filtration detects phosphorus content, protein content calculates polysaccharide and albumen ratio, the molecular weight determination and the KD0.3 response rate, GL-PP discrimination test, endotoxin content, sterility test are after the assay was approved every, are A group meningitis cocci capsular polysaccharide albumen coupling stock solution.(3) C group meningitis cocci capsular polysaccharide coupling stock solution: the preparation details of C group meningitis cocci polysaccharide is identical with the preparation method of A group meningitis cocci polysaccharide.C group meningitis cocci capsular polysaccharide is diluted to 4mg/ml, add Bromine cyanide. (CNBr) activated polysaccharide, 20～30 ℃ act on 1～1.5 hour down, transfer PH and keep PH9～11, continue after add adipic dihydrazide (ADH) 2.5～5mg/mg polysaccharide, keep PH8～10, reacted 30 minutes, stirred 10～20 hours at 2～8 ℃, small-molecule substance is removed in dialysis.CNBr residual volume, ADH derivation rate are surveyed in sampling.Add equivalent B group meningitis cocci outer membrane protein and mix with polysaccharide, add carbodiimide (EDAC) 15～25mg/ml mixture, 5～15 ℃ were reacted 1～1.5 hour, transferred PH5～7.Small-molecule substance is removed in the dialysis of coupling stock solution, 300KD film bag ultrafiltration and concentration, through the SepharoseCL-4B column chromatography, collect high-molecular weight coupling compound, aseptic filtration detects sialic acid content, protein content calculates polysaccharide and albumen ratio, the molecular weight determination and the KD0.3 response rate behind polysaccharide, albumen discrimination test, endotoxin content, the every assay approval of sterility test, are C group meningitis cocci capsular polysaccharide albumen coupling stock solution.
The preparation of combined vaccine: above-mentioned encephalitis b virus vaccinogen liquid, A group meningitis cocci capsular polysaccharide albumen coupling stock solution and C group meningitis cocci capsular polysaccharide albumen coupling stock solution are prepared with phosphate buffer, every dose of antigen final concentration is respectively: encephalitis b virus protein 10 μ g, A group meningitis cocci polysaccharide 5 μ g, C group meningitis cocci polysaccharide 5 μ g, B group meningitis cocci outer membrane protein 30 μ g.Every dose adds antigen stabilizing agent human albumin 0.12%, thimerosal 0.005%, accent pH6.5 again, is combined vaccine by 0.5/ dose of packing.
Embodiment 2
The preparation of encephalitis b virus vaccinogen liquid and meningococcal polysacharide and protein binding vaccinogen liquid and the preparation of combined vaccine.
Repeat the step described in the embodiment 1, different is when the preparation of combined vaccine, above-mentioned encephalitis b virus vaccinogen liquid, A group meningitis cocci capsular polysaccharide albumen coupling stock solution and C group meningitis cocci capsular polysaccharide albumen coupling stock solution are prepared with phosphate buffer, every dose of antigen final concentration is respectively: encephalitis b virus protein 20 μ g, A group meningitis cocci polysaccharide 20 μ g, C group meningitis cocci polysaccharide 20 μ g, B group meningitis cocci outer membrane protein 150 μ g.Every dose adds antigen stabilizing agent human albumin 0.12%, thimerosal 0.005%, accent pH7.5 again, is combined vaccine by 0.5/ dose of packing.
Embodiment 3
The safety testing of encephalitis B and meningitis combined vaccine
Safety to encephalitis B and meningitis combined vaccine is examined, and adopts mice, Cavia porcellus abnormal toxicity test method to examine its safety respectively.Select 250～350g cleaning level Cavia porcellus for use, the encephalitis B and the meningitis combined vaccine of 10 personal dosage inoculated in the abdominal cavity, and, injection preceding respectively at injection weighed, and observed reaction of inoculation at any time in back 7 days.Select 18～22g cleaning level level Balb/c strain mice for use, 1 personal dosage encephalitis B and meningitis combined vaccine inoculated in the abdominal cavity, and, injection preceding respectively at injection weighed, and observed reaction of inoculation at any time in back 7 days.Result of the test is listed in table 1.
The safety testing of table 1. encephalitis B and meningitis combined vaccine
| Animal | Body weight (g) before the inoculation | The observation period reaction of inoculation | Inoculate back 7 days body weight (g) | Conclusion |
| Cavia porcellus | ????315 | Cavia porcellus is good for and deposits no abnormal reaction | ????354 | Qualified |
| Cavia porcellus | ????306 | Cavia porcellus is good for and deposits no abnormal reaction | ????345 | Qualified |
| Mice | ????19.8 | Mice is good for and deposits no abnormal reaction | ????21.5 | Qualified |
| Mice | ????20.2 | Mice is good for and deposits no abnormal reaction | ????22.3 | Qualified |
| Mice | ????20.0 | Mice is good for and deposits no abnormal reaction | ????22.8 | Qualified |
| Mice | ????20.6 | Mice is good for and deposits no abnormal reaction | ????21.6 | Qualified |
| Mice | ????21.0 | Mice is good for and deposits no abnormal reaction | ????22.5 | Qualified |
Animal safety test shows, do not have in encephalitis B and the meningitis combined vaccine exogenous toxicant pollution, do not have unexpected unsafe factor, can guarantee the safety that human body uses.
Embodiment 4
Encephalitis b virus antigen is to immunogenic interference of hitchens and Hansen antigen and influence in the combined vaccine
Select for use 6 the week age BALB/C mice, be divided into combined vaccine group, AC group meningitis cocci combined vaccine group and matched group.Every group of 10 mices, every mouse subcutaneous injection contains combined vaccine and the AC group meningitis cocci polysaccharide conjugate vaccine of A, each 2.5 μ g of C group meningitis cocci polysaccharide, initial immunity 2 all backs booster immunizations 1 time, not time immunity blood sampling in back 7 days, adopt indirect elisa method to detect mice serum antibody titer (GMT), the ELISA method detects 1: 100 positive rate of mice serum and is not less than 80%, matched group is a normal saline, every mouse subcutaneous injection 0.5ml is with 2.1 times of positive criterions of the average light absorption value of control group mice serum (1: 100).The results are shown in Table 2.
Meningococcus immunogenicity of antigens in table 2. combined vaccine
| The vaccine kind | The A group antigen | The C group antigen | ||
| ????GMT | Sun rate of rotation % | ????GMT | Sun rate of rotation % | |
| AC group's combined vaccine | ????5861 | ????100 | ????5353 | ????100 |
| Combined vaccine | ????8792 | ????100 | ????7952 | ????100 |
The above results shows that combined vaccine and AC group meningitis cocci combined vaccine are not having significant difference aspect the positive rate of rotation of A, C group's polysaccharide antigen respectively, but truly have significant difference aspect GMT.GMT before A, the associating of C group meningitis cocci combined vaccine is respectively 5861,5353, and the GMT after the associating then is respectively 8792,7952, shows that the immunogenicity of A, C group's polysaccharide antigen has significance to improve (P＜0.01) after uniting with Vaccinum Encephalitis B.Further specify, the immunogenicity of associating back A, C group's polysaccharide antigen not only is not subjected to the antigenic interference of encephalitis b virus, obtains encephalitis b virus antigen synergism on the contrary, and enhancement effect has appearred in the meningitis immunogenicity of antigens in the combined vaccine.
Embodiment 5
Hitchens and Hansen antigen is to the interference and the influence of the scorching antigen immune originality of B-mode encephalovirus in the combined vaccine
Every kind of vaccine selects 20 of 12～14g mices, and immune Vero cell encephalitis B deactivation purified vaccine and combined vaccine 0.5ml are distinguished in every abdominal cavity, immunity twice, 7 days at interval.Just exempt from blood sampling after 15 days, 2～8 ℃ are spent the night.Next day separation of serum, 56 ℃ of deactivations in 30 minutes.In reducing with plaque and the measuring NAT, in and Strain be SA
14Strain and P
3Strain, result of the test sees Table 3.
Encephalitis b virus immunogenicity of antigens in table 3. combined vaccine
| The vaccine kind | NAT | |
| Viral SA neutralizes 14 | Viral P neutralizes 3 | |
| Encephalitis b deactivation purified vaccine | ??????1∶20 | ??????1∶20 |
| Combined vaccine | ??????1∶40 | ??????1∶40 |
The above results shows that combined vaccine and Vero cell encephalitis B deactivation purified vaccine have significant difference aspect NAT, and the antigenic NAT of encephalitis b virus significance after associating improves (P＜0.01).Further specify, associating back encephalitis b virus immunogenicity of antigens not only is not subjected to the interference of hitchens and Hansen antigen, obtains the synergism of hitchens and Hansen antigen on the contrary, and associating back encephalitis b virus immunogenicity of antigens shows enhancement effect.
Embodiment 6
Hitchens and Hansen antigen scorching antigen protection is renderd a service to B-mode encephalovirus interference and influence in the combined vaccine
Adopt immune white mice neutralizing antibody algoscopy.Neutralizing antibody is measured and is adopted plaque to reduce test.With reference to vaccine (R
AAnd R
B) and the neutralization test positive serum available from Nat'l Pharmaceutical ﹠ Biological Products Control Institute.Deactivation purified vaccine (T with the preparation of Vero cell culture
1), combined vaccine (T
2) and diluted respectively 1: 32 with reference to vaccine (R), peritoneal immunity body weight 12～14g mice is 10 respectively, every 0.5ml, immunity 2 times, 7 days at interval.The 2nd immunity blood sampling in back 7 days, separation of serum, the mice serum mixed in equal amounts in 56 ℃ of deactivations 30 minutes, is diluted positive serum, T on the same group
1Serum, T
2Serum and R serum, good with dilution respectively virus (about 200PFU/0.4ml) mixed in equal amounts.To dilute the dilution in 1: 2 again of good virus simultaneously,, put 37 ℃ of water-bath effects 90 minutes, inoculate 6 orifice plate BHK as virus control
21Cell, every hole 0.4ml cultivated 90 minutes for 37 ℃, added the culture medium covering of methylcellulose, in CO
2Cultivated 5 days in the incubator, dyeing, plaque counting calculates T
1, T
2With the plaque slip of R group to the virus control group.The plaque average of virus control group should be between 50～150, and the qualification determination standard is T 〉=(R
A+ R
B)/2-0.33 the results are shown in Table 4.
The antigenic protection of encephalitis b virus is renderd a service in table 4. combined vaccine
| The vaccine kind | The plaque slip | Neutralization index | Conclusion |
| Encephalitis b deactivation purified vaccine | ????22.15 | ????1.618 | Qualified |
| Combined vaccine | ????31.69 | ????1.827 | Qualified |
The above results shows that combined vaccine and Vero cell encephalitis B deactivation purified vaccine are having significant difference aspect the protection effectiveness (neutralization index), and the antigenic protection of encephalitis b virus is renderd a service after associating and improved (P＜0.01) by significance.Further specify, the interference that is not subjected to hitchens and Hansen antigen is renderd a service in encephalitis b virus antigenic protection in associating back, obtains the synergism of hitchens and Hansen antigen on the contrary, and encephalitis b virus antigenic protection in associating back is renderd a service and shown enhancement effect.
Claims (12)
1, a kind of combined vaccine is characterized in that comprising encephalitis b virus vaccine and meningococcus combined vaccine.
2, combined vaccine according to claim 1, it is characterized in that in every dose of human combined vaccine of described encephalitis b virus vaccine, contain encephalitis b virus albumen 5～50 μ g, A group meningitis cocci polysaccharide 5～50 μ g, C group meningitis cocci polysaccharide 5～50 μ g, B group meningitis cocci outer membrane protein 30～300 μ g.
3, combined vaccine according to claim 1 is characterized in that described encephalitis b virus vaccine is the vaccine that a kind of complete virion that is obtained through cell culture, results, deactivation, ultrafiltration and concentration, purification by encephalitis b virus prepares.
4, combined vaccine according to claim 1, it is characterized in that described encephalitis b virus vaccine is the complete virion that will obtain, through chemical cracking agent cracking, extract the fragment that comprises outer virionic membrane and furcella, the encephalitis b virus split vaccine of making again.
5,, it is characterized in that described encephalitis b virus vaccine is by encephalitis b virus SA according to any one described combined vaccine of claim 3-4
14Strain, SA
14-14-2Strain, P
3Arbitrary Strain prepares in strain or the Nakayama strain.
6,, it is characterized in that the cell in the described cell culture is Vero cell, hamster kidney cell, human diploid cell according to any one described combined vaccine of claim 3.
7, combined vaccine according to claim 1, it is characterized in that described meningococcus combined vaccine be a kind of by A group meningitis cocci capsular polysaccharide, C group meningitis cocci capsular polysaccharide respectively with the link coupled combined vaccine of a protein carrier.
8, combined vaccine according to claim 7, it is characterized in that described A group meningitis cocci polysaccharide is from bacterial strain CMCC (B) 29201, described C group meningitis cocci polysaccharide is from bacterial strain CMCC (B) 29205, and described B group meningitis cocci outer membrane protein is from bacterial strain CMCC (B) 29356 and/or CMCC (B) 29361.
9, combined vaccine according to claim 1, it is characterized in that described meningococcus combined vaccine be a kind of by A group, C group, W135 group and Y group meningitis cocci capsular polysaccharide respectively with the mutually link coupled combined vaccine of a protein carrier.
10,, it is characterized in that described meningococcus combined vaccine protein carrier is selected from B group meningitis cocci outer membrane protein, tetanus toxoid, diphtheria toxoid, avirulence diphtheria variant (CRM197) toxin according to claim 7 or 9 described combined vaccines.
11, combined vaccine according to claim 1 is characterized in that combined vaccine contains aluminium adjuvant.
12, combined vaccine according to claim 11 is characterized in that described aluminium adjuvant comprises aluminium hydroxide and/or aluminum phosphate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101194148A CN1314449C (en) | 2003-12-10 | 2003-12-10 | Combined vaccine composed of viral of Japanese b encephalitis and vaccine of brain fever cocci |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101194148A CN1314449C (en) | 2003-12-10 | 2003-12-10 | Combined vaccine composed of viral of Japanese b encephalitis and vaccine of brain fever cocci |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1626242A true CN1626242A (en) | 2005-06-15 |
| CN1314449C CN1314449C (en) | 2007-05-09 |
Family
ID=34761366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101194148A Expired - Lifetime CN1314449C (en) | 2003-12-10 | 2003-12-10 | Combined vaccine composed of viral of Japanese b encephalitis and vaccine of brain fever cocci |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1314449C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110081376A1 (en) * | 2008-06-04 | 2011-04-07 | The Chemo-Sero-Therapeutic Research Institute | Method for using inactivated japanese encephalitis virus particles as adjuvant |
| CN108295253A (en) * | 2018-04-17 | 2018-07-20 | 北京成大天和生物科技有限公司 | A kind of A, C group meningitis cocci-b types haemophilus influenzae/encephalitis B combined vaccine |
| CN111281972A (en) * | 2020-03-24 | 2020-06-16 | 北京成大天和生物科技有限公司 | Combined vaccine consisting of ABCYW135 group meningococcus vaccine and encephalitis B vaccine |
-
2003
- 2003-12-10 CN CNB2003101194148A patent/CN1314449C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110081376A1 (en) * | 2008-06-04 | 2011-04-07 | The Chemo-Sero-Therapeutic Research Institute | Method for using inactivated japanese encephalitis virus particles as adjuvant |
| CN102112153A (en) * | 2008-06-04 | 2011-06-29 | 一般财团法人化学及血清疗法研究所 | Use of inactivated japanese encephalitis virus particle as adjuvant |
| US9114098B2 (en) | 2008-06-04 | 2015-08-25 | The Chemo-Sero-Therapeutic Research Institute | Method for using inactivated Japanese encephalitis virus particles as adjuvant |
| CN108295253A (en) * | 2018-04-17 | 2018-07-20 | 北京成大天和生物科技有限公司 | A kind of A, C group meningitis cocci-b types haemophilus influenzae/encephalitis B combined vaccine |
| CN111281972A (en) * | 2020-03-24 | 2020-06-16 | 北京成大天和生物科技有限公司 | Combined vaccine consisting of ABCYW135 group meningococcus vaccine and encephalitis B vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1314449C (en) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101287488B (en) | Multiple vaccination including serogroup C meningococcus | |
| RU2023448C1 (en) | Method for manufacturing vaccine against various pathogenic serotypes of group b neisser's meningitis | |
| JPS59141523A (en) | Bonded h.influenza b vaccine | |
| CN1709505B (en) | Polyvalent bacteria capsule polysaccharide-protein conjugate combined vaccine | |
| CN106999569B (en) | Improved method for inactivation of enteroviruses, adjuvant adsorption and resulting dose-reduced vaccine composition | |
| CN105963692B (en) | Combined vaccine for preventing hand-foot-and-mouth disease | |
| CN103394082B (en) | Multivalent immunogenic composition | |
| CN103386126B (en) | Multivalent immunogenic composition containing enterovirus antigens | |
| CN101507814B (en) | Multi-component antigen acellular pertussis vaccine and preparation method thereof | |
| US20220267419A1 (en) | Human Immunoglobulin Against Methicillin-Resistant Staphylococcus Aureus, Preparation Method Therefor, And Use Thereof | |
| CN101934077A (en) | Multivalent meningococcal derivatized polysaccharide-proteinconjugates and vaccine | |
| CN103561763A (en) | Immunogenic bordetella bronchiseptica compositions | |
| CN1712068A (en) | Diploid-cell rabies vaccine and purified rabies vaccine, freeze-drying preparation and water injection thereof | |
| WO2024125100A1 (en) | Bivalent inactivated ev71-ca16 vaccine, method for preparing same, and use thereof | |
| CN105999256B (en) | Combined vaccine for preventing hand-foot-and-mouth disease | |
| CN1314449C (en) | Combined vaccine composed of viral of Japanese b encephalitis and vaccine of brain fever cocci | |
| CN106075423B (en) | Combined vaccine for preventing hand-foot-and-mouth disease | |
| EP1645283A1 (en) | Combination vaccine | |
| CN111840532A (en) | Live vaccine for preventing viral infectious diseases | |
| McDonnell et al. | Immunization | |
| CN101732704B (en) | Method for preparing inactivated bivalent vaccine against rabbit hemorrhagic disease and pasteurella multocida disease | |
| CN1168501C (en) | Poly saccharide-protein combination vaccine | |
| CN108295253A (en) | A kind of A, C group meningitis cocci-b types haemophilus influenzae/encephalitis B combined vaccine | |
| CN1209163C (en) | Meningococcal vaccine and its preparing method | |
| CN101559222A (en) | Combined vaccine bonding bacterial polysaccharides and protein for human |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ZHANG GUOMING Effective date: 20050603 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20050603 Address after: Beijing City, Fengtai District Muxiyuan Pearl River Ascot building 2302 room 15 Applicant after: Xue Ping Address before: Beijing City, Fengtai District Muxiyuan Pearl River Ascot building 2302 room 15 Applicant before: Xue Ping Co-applicant before: Zhang Guoming |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SHANGHAI RONGSHENG BIOTECH CO.,LTD. Assignor: Xue Ping Contract fulfillment period: 2007.12.20 to 2012.12.20 Contract record no.: 2008990000335 Denomination of invention: Combined vaccine composed of viral of Japanese b encephalitis and vaccine of brain fever cocci Granted publication date: 20070509 License type: Exclusive license Record date: 20080822 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.12.20 TO 2012.12.20 Name of requester: SHANGHAI RONGSHENG BIOLOGY PHARMACY CO., LTD. Effective date: 20080822 |
|
| ASS | Succession or assignment of patent right |
Owner name: CHENGDU ANTEJIN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: XUE PING Effective date: 20131203 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 101318 SHUNYI, BEIJING TO: 610041 CHENGDU, SICHUAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131203 Address after: 610041 No. 88 Park South Road, hi tech Zone, Sichuan, Chengdu Patentee after: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Address before: 101318 Beijing City, Shunyi District Vanke City Garden No. 902 cloud Fengge Patentee before: Xue Ping |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Combined vaccine composed of viral of Japanese b encephalitis and vaccine of brain fever cocci Effective date of registration: 20191021 Granted publication date: 20070509 Pledgee: Chengdu Branch of China Guangfa Bank Co.,Ltd. Pledgor: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Registration number: Y2019990000366 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: No.88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Patentee after: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Address before: No.88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Patentee before: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. |
|
| CP01 | Change in the name or title of a patent holder | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221115 Granted publication date: 20070509 Pledgee: Chengdu Branch of China Guangfa Bank Co.,Ltd. Pledgor: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Registration number: Y2019990000366 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20221115 Registration number: Y2019990000366 Pledgor after: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Pledgor before: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. |
|
| PM01 | Change of the registration of the contract for pledge of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070509 |
|
| CX01 | Expiry of patent term |